Founders of MedBiome receive 2.9M$ to further develop the RapidAIM microbiome drug screening platform
Dr. Daniel Figeys, Dr. Alain Stintzi and their teams at the University of Ottawa are further developing the RapidAIM platform. The team is currently developing commercial applications, which include a fully automated, high-throughput prototype of the RapidAIM platform.